Business Wire

ONWARD Announces Participation at Upcoming Events in October

Share

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announced that management will participate in the following upcoming events in October:

  • Investors’ Day Geneva
    October 5, 2022 
    Geneva, Switzerland 
    Dave Marver, CEO, will give a company presentation.
  • The 3rd Annual Reeve Summit
    October 13-14, 2022 
    Washington, DC USA 
    Dave Marver will participate in a keynote session, The Power of Partnership to Speed Cures to Market, with Marco Baptista, Chief Scientific Officer, Christopher & Dana Reeve Foundation.
  • Oppenheimer Healthcare Showcase
    October 18, 2022 
    Palo Alto, CA USA 
    Lara Smith Weber, CFO, will give a company presentation and participate in 1:1 meetings. 
  • VFB Soirées (Flemish Federation of Investors) 
    October 27, 2022 
    Virtual event at 19:30 CET 
    Dave Marver, CEO, will give a company presentation.

Information on upcoming conferences is available in the investor section of the ONWARD website at https://ir.onwd.com/news-events.

About ONWARD Medical

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal-cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life.

ONWARD has received three Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IMand ARC-EX. ARC-EX is an external, non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top line data were reported in September 2022 from the company’s first pivotal study, called Up-LIFT, evaluating the ability of ARC-EX Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead that is placed near the spinal cord. The company completed its first-in-human use of the ARC-IM neurostimulator in May 2022.

ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It has substantial operations in Lausanne, Switzerland, and a growing U.S. presence in Boston, Massachusetts. For additional information about the company, please visit ONWD.com. To access our 2022 Financial Calendar, please visit IR.ONWD.com.

Disclaimer

Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Company Enquiries:
info@onwd.com

For Media Enquiries:
MC Services AG
US: Laurie Doyle, P: +1 339 832 0752
Europe: Dr. Johanna Kobler, Katja Arnold, Kaja Skorka, P: +49 89 210 228 0
media@onwd.com

For Investor Enquiries:
investors@onwd.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EODev Launches a New Range of High Capacity Zero-emission Hydrogen Power Generators6.12.2022 15:18:00 CET | Press release

After less than three years in business and close to 100 GEH2® (110kVA) and onboard REXH2®(70kW) electro-hydrogen power generators sold across the world, French manufacturer EODev announces the commercialization of new products from 10kVA to 1,750kVA. The first models will enter production in 2024 and will be available for order from mid-2023. EODev's assembly line near Paris already delivers one 110kVA GEH2® per day. The objective being to avoid the emission of 30 million tons of CO2 over the next 10 years, EODev now initiates the second phase of its product development by expanding its range to offer new high power "plug & play" solutions for existing customers, such as equipment rental leaders Loxam and United Rentals, and for new markets with high power back up or fast EV charging in mind. The acceleration of our deployment continues. We have proven the validity of our products throughout the world and built a leading know-how in the design and management of fuel cell systems over

Rimini Street Launches Rimini Connect™ to Help Organizations Future-Proof and Solve Continuously Evolving and Growing Integration and Interoperability Challenges6.12.2022 15:01:00 CET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products, and a Salesforce partner, has launched Rimini Connect™, a new suite of integration and interoperability solutions that allows for easy resolution of continuously changing integration and interoperability requirements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130005063/en/ Rimini Street announced launch of Rimini Connect™, a new suite of integration and interoperability solutions that allows for easy resolution of continuously changing integration and interoperability requirements. (Graphic: Business Wire) For years, Rimini Street has provided proven and proactive integration and interoperability solutions for its clients’ enterprise software applications, browsers, infrastructure, and email. Three initial solutions are now being brought tog

Gurobi’s Expert-Led Team Provides In-Depth Technical Guidance and Support6.12.2022 15:00:00 CET | Press release

Gurobi Optimization, LLC, the leader in decision intelligence technology and creator of the world’s fastest mathematical optimization solver, recently announced the rebranding of its support team as “Gurobi Experts – Technical Advisory and Support Team.” This team of 15+ PhD-level optimization specialists is passionate about helping customers succeed with optimization and can provide comprehensive guidance on Gurobi products and mathematical optimization. Matthias Miltenberger, Optimization Support Manager, explained that the reasoning behind the rebrand stemmed from some common misunderstandings about the word “support.” “There’s this idea that ‘support’ means sitting in a call center all day with headphones on,” said Miltenberger. “Most people hear that word and think of experiences they’ve had calling up their phone or internet provider, which are often unpleasant experiences. And the assumption is that they’re not really talking to experts, so we definitely wanted to change that mi

Mavenir Wins Most Innovative Cloud Product Award for Telco Cloud Solution from Light Reading6.12.2022 15:00:00 CET | Press release

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, has won the Most Innovative Cloud Product Award from Leading Lights for its Telco Cloud Solution. Mavenir’s Telco cloud solution provides CSPs a complete, end-to-end network software portfolio that is 100% cloud-native and runs in any cloud environment private, public, and hybrid. Cloud-native is required to support the 5G heterogenous environment in an automated manner, with microservices implemented in containers providing the placement of workloads at the right location. “Mavenir’s cloud-first approach to networks is recognized as a path to the future,” said Bejoy Pankajakshan, EVP, Chief Technology and Strategy Officer at Mavenir. “We are empowering operators to take full advantage of cloud technology with reliable, carrier-grade, high-performance solutions with security and on-demand scaling.” Mavenir’s solution is uniq

Medidata Launches New myMedidata Native App to Expedite Study Start Up and Improve Patient Experience6.12.2022 15:00:00 CET | Press release

Medidata, a Dassault Systèmes company, launched a new patient-centric native myMedidata app, designed to provide trial participants with another option for a seamless platform experience and a single login for all their remote trial activities. The app will feature all of the myMedidata patient-centric solutions, with an initial focus on eCOA (electronic clinical outcome assessments). The myMedidata app is available on iOS and Android and can be used both on the patients’ own devices (BYOD) or via a provisioned device. “Our latest addition to myMedidata brings an innovative app to patients designed in concert with our patient insights team, customer feedback, and the experiences derived from running the world’s biggest DCTs over the last twenty years,” said Matt Noble, senior vice president, Medidata Patient Cloud. “Medidata is leveraging its unique insights from sponsors, CROs, sites, and patients to make a meaningful difference in the clinical trial experience.” Unique to the industr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom